Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial

被引：0
|
作者：
Huyghe, N. [1 ]
Benidovskaya, E. [1 ]
Masoodi, T. [2 ]
Carrasco, J. [3 ]
De Cuyper, A. [4 ]
Sinapi, I. [3 ]
Vempalli, F. [2 ]
Verstraelen, E. [5 ]
Goffette, P. [5 ]
Ghaye, B. [5 ]
Papier, M.
Bedognetti, D. [2 ]
van Maanen, A. [5 ]
Castella, M-L. [5 ]
Galon, J. [6 ]
van den Eynde, M. [4 ]
机构：
[1] UCLouvain Univ Catholique Louvain, IIREC MIRO ONCO, Woluwe St Lambert, Belgium
[2] Sidra Med & Res Ctr, Al Rayyan, Qatar
[3] GHdC Grand Hop Charleroi Site Notre Dame, Med Oncol Dept, Charleroi, Belgium
[4] Clin Univ St Luc UCLouvain St Luc, Digest Oncol Dept, Woluwe St Lambert, Belgium
[5] Inst Roi Albert II Clin Univ St Luc, St Luc, Brussels, Belgium
[6] Cordeliers Res Ctr, Lab Integrat Canc Immunol, INSERM Team 15, Paris, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2237P
引用
收藏
页码：S1152 / S1152
页数：1
相关论文
共 50 条
  • [1] Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
    van den Eynde, M.
    Huyghe, N.
    Sinapi, I.
    De Cuyper, A.
    Verstraelen, E.
    Goffette, P.
    Ghaye, B.
    Papier, M.
    Bedognetti, D.
    van Maanen, A.
    Castella, M-L.
    Galon, J.
    Carrasco, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S450 - S450
  • [2] Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Characterization of the circulating immune response in the AVETUXIRI phase II trial
    Benidovskaya, E.
    Huyghe, N.
    Carrasco, J.
    De Cuyper, A.
    Sinapi, I.
    Verstraelen, E.
    Goffette, P.
    Ghaye, B.
    Papier, M.
    van Maanen, A.
    Castella, M-L.
    Galon, J.
    van den Eynde, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S56 - S56
  • [3] Interim analysis of the phase II AVETUXIRI trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Huyghe, Nicolas
    De Cuyper, Astrid
    Sinapi, Isabelle
    Vempalli, Fazulur Rehaman
    Rinchai, Darawan
    Beyaert, Simon
    Verstraelen, Eleonore
    Goffette, Pierre
    Ghaye, Benoit
    Gilet, Melanie
    Van Maanen, Aline
    Castella, Marie-Laure
    Mlecnik, Bernhard
    Carrasco, Javier
    Galon, Jerome
    Bedognetti, Davide
    Van den Eynde, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)-A proof of concept, open-label, nonrandomized phase IIa study.
    Van den Eynde, Marc
    Huyghe, Nicolas
    De Cuyper, Astrid
    Sinapi, Isabelle
    Ferrier, Marie
    Gilet, Melanie
    Van Maanen, Aline
    Castella, Marie-Laure
    Galon, Jerome
    Carrasco, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [5] Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Bocobo, Andrea Grace
    Wang, Renee
    Behr, Spencer
    Carnevale, Julia C.
    Cinar, Pelin
    Collisson, Eric Andrew
    Fong, Lawrence
    Keenan, Bridget P.
    Kidder, Wesley Allen
    Ko, Andrew H.
    Kolli, Kanti Pallav
    Kennedy, Megan
    Laffan, Angela
    Piawah, Sorbarikor
    Pollak, Marin
    Schwartz, Gabriel
    Whitman, Julia
    Zhang, Li
    Van Loon, Katherine
    Atreya, Chloe Evelyn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Correlative analysis of metformin and nivolumab combination in treatment-refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Farran, Batoul
    Switchenko, Jeffrey M.
    Khalil, Lana
    Shaib, Walid L.
    Olson, Brian
    Ruggieri, Amanda
    Wu, Christina
    Alese, Olatunji B.
    Diab, Maria
    Lesinski, Gregory B.
    El-Rayes, Bassel
    Akce, Mehmet
    CANCER RESEARCH, 2022, 82 (12)
  • [7] Phase II study of cabozantinib and nivolumab in refractory metastatic microsatellite stable (MSS) colorectal cancer (CRC).
    Leal, Alexis Diane
    Blatchford, Patrick Jud
    Kim, Sunnie S.
    Lentz, Robert William
    Kemme, Douglas Jerome
    Russen, McKenna
    Friedrich, Tyler
    Mathew, Lynn
    Hoyer, Robert John
    Kono, Scott Arthur
    Baiyee Toegel, Emily
    Bagby, Stacey M.
    Dominguez, Adrian
    Davis, S. Lindsey
    Pitts, Todd
    Lieu, Christopher Hanyoung
    Messersmith, Wells A.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 229 - 229
  • [8] Irinotecan, cetuximab, and bevacizumab (CBI) versus irinotecan, cetuximab, and placebo (CI) in irinotecan-refractory metastatic colorectal cancer (mCRC): Results from an ACCRU network randomized phase II trial
    Lipsyc-Sharf, Marla
    Ou, Fang-Shu
    Yurgelun, Matthew B.
    Rubinson, Douglas Adam
    Schrag, Deborah
    Dakhil, Shaker R.
    Stella, Philip J.
    Weckstein, Douglas Jay
    Wender, Donald B.
    Faggen, Meredith Gail
    Zemla, Tyler
    Heying, Erica N.
    Schuetz, Samantha R.
    Noble, Stephanie
    Meyerhardt, Jeffrey A.
    Bekaii-Saab, Tanios S.
    Fuchs, Charles S.
    Ng, Kimmie
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [9] A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).
    Parikh, Aparna Raj
    Clark, Jeffrey William
    Wo, Jennifer Yon-Li
    Yeap, Beow Y.
    Allen, Jill N.
    Blaszkowsky, Lawrence Scott
    Ryan, David P.
    Giantonio, Bruce J.
    Weekes, Colin D.
    Zhu, Andrew X.
    Van Seventer, Emily E.
    Matlack, Lauren
    Foreman, Bronwen
    Ly, Leilana
    Drapek, Lorraine C.
    Ting, David Tsai
    Corcoran, Ryan Bruce
    Hong, Theodore S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Phase II trial of nivolumab and metformin in patients with treatment refractory microsatellite stable metastatic colorectal cancer
    Akce, Mehmet
    Rupji, Manali
    Switchenko, Jeffrey M.
    Shaib, Walid Labib
    Wu, Christina
    Alese, Olatunji B.
    Diab, Maria
    Lesinski, Gregory B.
    El-Rayes, Bassel F.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345